All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ide-Cel Is Effective, Safe for Patients With R/R Multiple Myeloma and Renal Insufficiency

February 17th 2023

Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.

Bispecific LV20.19 CAR T Cells Induce 92% CR Rate in Relapsed/Refractory Mantle Cell Lymphoma

February 17th 2023

Bispecific CAR T-cell therapy targeting both CD20 and CD19 cells induced a 90-day complete response rate of 92% in patients with relapsed/refractory mantle cell lymphoma.

Fox Chase’s Cihangir Duy Receives an American Society of Hematology 2023 Scholar Award

February 17th 2023

Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology 2023 Junior Faculty Scholar Award in basic/translational research.

Darolutamide Demonstrates Long-term Safety in nmCRPC

February 16th 2023

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC

February 16th 2023

The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.

Lutetium 177 PSMA-617 Following Radium-223 Is Active and Safe in mCRPC

February 16th 2023

Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.

Talazoparib Plus Enzalutamide Improves rPFS in First-line mCRPC

February 16th 2023

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.

Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC

February 16th 2023

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Brexu-cel Shows Survival Benefit in Relapsed/Refractory B-cell ALL, Regardless of Prior Treatment

February 16th 2023

Brexucabtagene autoleucel demonstrated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of prior lines of treatment or exposure to blinatumomab or allogeneic stem cell transplant, according to data from subgroup analyses of the ZUMA-3 trial.

MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCT

February 16th 2023

The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.

JCAR021 Showcases High Response Rates, but Mixed Safety Data in Relapsed/Refractory Large B-cell Lymphoma

February 16th 2023

The fully-human scFv CD19-targeted CAR T-cell therapy JCAR021 elicited durable responses but with a high rate of neurotoxicity when administered at a dose of 7 x 106 cells/kg in patients with relapsed or refractory large B-cell lymphoma, according to data from a phase 1/2 trial.

Freshly Infused Zamtocabtagene Autoleucel Shows Encouraging Activity in Relapsed/Refractory DLBCL

February 16th 2023

The dual CD19- and CD20-directed, freshly administered CAR T-cell therapy zamtocabtagene autoleucel elicited a high response rate with deepening responses over time in patients with relapsed/refractory diffuse large B-cell lymphoma.

Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger

February 16th 2023

An independent data monitoring committee has recommended that a phase 3 trial evaluating uproleselan plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia should continue to the planned overall survival event trigger.

Tumor Microbiome Linked to Immunotherapy Success in Sarcoma Patients

February 16th 2023

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer

February 16th 2023

Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.

Ponatinib Plus Reduced-Intensity Chemotherapy Steps Up as Potential New SOC in Newly Diagnosed Ph+ ALL

February 15th 2023

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Toripalimab/Chemo Improves OS in Recurrent/Metastatic Nasopharyngeal Carcinoma in Final JUPITER-02 Trial Analysis

February 15th 2023

Toripalimab plus gemcitabine and cisplatin demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone as frontline therapy in patients with recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Priority Review to Avasopasem for Radiotherapy-Induced Severe Oral Mucositis

February 15th 2023

The FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment.

RxPONDER Analysis Reveals Racial Disparities in HR+/HER2– Breast Cancer

February 15th 2023

Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.

Neoadjuvant Nivolumab Provides Sustained Efficacy in Resected NSCLC

February 15th 2023

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.